Abstract
“The clinical impact of aspirin resistance with cardiovascular events is now becoming evident, with aspirin nonresponders having nearly a threefold increased risk of cardiovascular death” Aspirin resistance is an increasingly recognized phenomenon denoting a diminished platelet inhibitory effect of aspirin. It has been reported in approximately 10–30% of patients taking aspirin. The clinical impact of aspirin resistance with cardiovascular events is now becoming evident, with aspirin nonresponders having nearly a threefold increased risk of cardiovascular death. The mechanisms for this phenomenon and methods to treat it are still unclear. More research is necessary before recommendations for clinical practice can be made. Aspirin was the first antiplatelet drug used in
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
